Overview

This trial is active, not recruiting.

Condition candidiasis
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Start date September 2001
End date April 2005
Trial size 926 participants
Trial identifier NCT00138502, 02-050

Summary

The purpose of the study is to test the hypothesis that a subpopulation of patients with candiduria are at significant risk for disseminated disease and would benefit from treatment, while others are at low risk from complications and therefore require no antifungal therapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: 1. Subjects with fungi isolated from the urine of any colony count. 2. Patients seen at either Harbor-UCLA Medical Center or Cedars Sinai Medical Center. Exclusion Criteria: 1. Persons with a previously positive urine fungal culture during the current hospital admission.

Additional Information

Official title The Significance of Funguria In Hospitalized Patients
Description This protocol will attempt to generate a detailed clinical profile of patients with funguria and identify subgroups of patients with funguria at high risk for candiduria and determine the relative risks for obtaining candiduria. In addition, it will look at identifying subgroups of patients with funguria at high risk for candidemia and identifying subgroups of patients with funguria at high risk for death. Finally, it will attempt to determine if funguria independently predicts fungemia or death. Data will be complemented by surveillance of a comparable population without funguria.
Trial information was received from ClinicalTrials.gov and was last updated in August 2010.
Information provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID).